Clinical data of 34 patients with follicular lymphoma and pretreatment circulating t(14;18)-positive cells
. | n . | % . |
---|---|---|
Sex | ||
Male | 21 | 62 |
Female | 13 | 38 |
Age | ||
Median (y) | 52 | |
Range (y) | 30-79 | |
Ann Arbor stage | ||
Stage II bulky or III | 11 | 32 |
Stage IV | 23 | 68 |
Systemic symptoms | 7 | 21 |
Bulky disease | 17 | 52 |
Bone marrow involvement* | 23 | 72 |
Leukemic | 2 | 6 |
Previous wait-and-see policy | ||
n | 7 | 21 |
Median period (mo) | 20 | |
Range (mo) | 9-32 | |
Response to 8 CVP + IFN | ||
Complete remission | 16 | 44 |
Partial remission | 11 | 34 |
Stable disease | 2 | 6 |
Progressive disease | 5 | 16 |
End of protocol treatment† | ||
Insufficient response to induction | 7 | 29 |
Toxicity of induction | 3 | 13 |
Progression during maintenance | 9 | 37 |
Toxicity of maintenance | 5 | 21 |
. | n . | % . |
---|---|---|
Sex | ||
Male | 21 | 62 |
Female | 13 | 38 |
Age | ||
Median (y) | 52 | |
Range (y) | 30-79 | |
Ann Arbor stage | ||
Stage II bulky or III | 11 | 32 |
Stage IV | 23 | 68 |
Systemic symptoms | 7 | 21 |
Bulky disease | 17 | 52 |
Bone marrow involvement* | 23 | 72 |
Leukemic | 2 | 6 |
Previous wait-and-see policy | ||
n | 7 | 21 |
Median period (mo) | 20 | |
Range (mo) | 9-32 | |
Response to 8 CVP + IFN | ||
Complete remission | 16 | 44 |
Partial remission | 11 | 34 |
Stable disease | 2 | 6 |
Progressive disease | 5 | 16 |
End of protocol treatment† | ||
Insufficient response to induction | 7 | 29 |
Toxicity of induction | 3 | 13 |
Progression during maintenance | 9 | 37 |
Toxicity of maintenance | 5 | 21 |